Pharma Mar

PHM · BME · EUR

€71.40+0.92%+€0.65

Close · October 2, 2026

At a glance

Revenue growth: +26.61%; 2025 vs 2024
Net income growth: +187.03%; 2025 vs 2024
Net margin: 33.9%; 2024: 14.9%

Financial data

Amounts in millions of EUR; per-share values in EUR; shares in millions.

Balance sheet · Quarterly
Item	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023
Total assets	394	385	395	342	348	333	350	333	317	334	341	349
Current assets	281	273	283	243	249	236	250	238	224	241	253	261
Cash and equivalents	19.3	48.9	17.8	49.7	21.6	60.3	63.2	34.8	19.3	35.7	60.0	70.0
Short-term investments	150	119	149	96.9	106	80.6	91.3	110	116	124	103	104
Receivables	47.9	40.0	39.4	33.5	59.8	36.8	34.7	33.7	30.0	26.9	27.6	30.2
Inventory	49.5	53.1	50.6	53.0	49.5	50.5	50.9	47.8	47.2	43.5	39.3	34.9
Net property, plant and equipment	60.0	59.7	60.1	57.0	57.7	58.3	57.8	57.7	54.7	53.7	34.5	43.0
Other intangible assets	4.0	3.8	1.4	1.2	1.1	1.0	1.0	1.2	1.4	1.7	1.2	2.0
Long-term investments	0.6	0.6	0.6	0.8	0.8	1.4	2.5	3.8	4.5	4.7	6.1	11.2
Current liabilities	98.4	89.2	93.9	88.9	87.8	79.5	82.7	89.4	87.9	92.3	95.9	86.6
Accounts payable	38.9	43.8	40.9	43.8	37.1	42.0	38.8	35.2	32.8	34.6	29.2	21.3
Long-term debt	32.1	33.2	35.6	36.6	37.6	38.6	39.9	41.0	26.0	25.9	27.0	26.9
Total debt	45.8	47.5	49.4	—	51.4	51.9	—	—	—	—	—	—
Total liabilities	143	136	143	144	147	136	141	151	136	141	147	143
Total equity (incl. minority)	251	250	252	198	202	197	208	182	181	193	193	206
Retained earnings	240	235	234	173	188	165	168	148	144	144	142	149